NASDAQ:NAMS NewAmsterdam Pharma 3/31/2026 Earnings Report $35.42 -1.14 (-3.12%) Closing price 04:00 PM EasternExtended Trading$34.81 -0.61 (-1.72%) As of 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast NewAmsterdam Pharma EPS ResultsActual EPS-$0.40Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ANewAmsterdam Pharma Revenue ResultsActual Revenue$3.04 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ANewAmsterdam Pharma Announcement DetailsQuarterDate3/31/2026TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AUpcoming EarningsNewAmsterdam Pharma's Q2 2026 earnings is estimated for Wednesday, August 5, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, August 6, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesEarnings HistoryCompany Profile NewAmsterdam Pharma Earnings HeadlinesNewAmsterdam Pharma to Participate at Upcoming Investor Conferences in JuneMay 28 at 8:00 AM | globenewswire.comNewAmsterdam Pharma Company N.V.May 21, 2026 | edition.cnn.comJune 12: $100 Turns Into $100,000?The SpaceX IPO is scheduled for June 12, and former tech executive Jeff Brown - who identified Bitcoin, Tesla, and Nvidia before major runs - says the window to get in early is closing fast. Brown is showing investors how to claim a stake in Elon Musk's company before it hits the public markets. Once the IPO happens, this pre-public opportunity disappears.May 28 at 1:00 AM | Brownstone Research (Ad)NewAmsterdam Pharma Company N.V. (NAMS) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 13, 2026 | seekingalpha.comNewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Reported Earnings Last Week And Analysts Are Already Upgrading Their EstimatesMay 12, 2026 | finance.yahoo.comNewAmsterdam Pharma Company N.V. (NAMS) Discusses Clinical Development Update and Interim Analysis Plans for PREVAIL Trial - SlideshowMay 11, 2026 | seekingalpha.comSee More NewAmsterdam Pharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like NewAmsterdam Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on NewAmsterdam Pharma and other key companies, straight to your email. Email Address About NewAmsterdam PharmaNewAmsterdam Pharma (NASDAQ:NAMS), Inc. is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism. The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation. These investigational compounds are designed to improve glycemic control, support weight management and reduce cardiometabolic risk factors. NewAmsterdam Pharma’s programs emphasize oral delivery formats and aim to provide differentiated safety and efficacy profiles compared with existing therapies. Headquartered in the United States, NewAmsterdam Pharma leverages a network of research collaborations with academic institutions and industry partners to accelerate its discovery and development activities. The company’s strategic alliances support advancement of its clinical candidates through regulatory milestones and position it to pursue global development and commercialization opportunities for patients with metabolic disorders. View NewAmsterdam Pharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Snowflake and the Snowballing Impact of its AI FlywheelThis Quantum Computing Stock May Be Closer to a Breakout Than You ThinkMicrosoft Is Spending Billions on AI, But Investors Aren’t Buying ItSemtech’s Explosive Rally May Only Be Getting StartedBath & Body Works Stock Surged Despite Falling Sales—Here’s WhyAbercrombie Rallies as Strong Q1 Earnings Extend Winning StreakDick’s Sporting Goods Isn’t Done Winning Yet Upcoming Earnings Hewlett Packard Enterprise (6/1/2026)Palo Alto Networks (6/2/2026)Broadcom (6/3/2026)CrowdStrike (6/3/2026)Medtronic (6/3/2026)Ciena (6/4/2026)Oracle (6/10/2026)Adobe (6/11/2026)Accenture (6/18/2026)FedEx (6/23/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
